158 related articles for article (PubMed ID: 28477739)
1. Vincristine-induced peripheral neuropathy in children with cancer: A systematic review.
van de Velde ME; Kaspers GL; Abbink FCH; Wilhelm AJ; Ket JCF; van den Berg MH
Crit Rev Oncol Hematol; 2017 Jun; 114():114-130. PubMed ID: 28477739
[TBL] [Abstract][Full Text] [Related]
2. [A cohort study of vincristine-induced peripheral neuropathy in children].
Li C; Jin J; Huang J; Yang XY; Li Y; Yan YY; Yang C
Zhongguo Dang Dai Er Ke Za Zhi; 2023 May; 25(5):470-475. PubMed ID: 37272172
[TBL] [Abstract][Full Text] [Related]
3. Prospective assessment of vincristine-induced peripheral neuropathy in paediatric acute lymphoblastic leukemia.
Li T; Kandula T; Cohn RJ; Kiernan MC; Park SB; Farrar MA
Clin Neurophysiol; 2023 Oct; 154():157-168. PubMed ID: 37633123
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial on the effect of 1-hour infusion of vincristine versus push injection on neuropathy in children with cancer (final analysis).
Uittenboogaard A; van den Berg MH; Abbink FCH; Twisk JWR; van der Sluis IM; van den Bos C; van den Heuvel-Eibrink MM; Segers H; Chantrain C; van der Werff Ten Bosch J; Willems L; Kaspers GJL; van de Velde ME
Cancer Med; 2023 Oct; 12(19):19480-19490. PubMed ID: 37732486
[TBL] [Abstract][Full Text] [Related]
5. Dapsone improves the vincristine-induced neuropathic nociception by modulating neuroinflammation and oxidative stress.
Shayesteh S; Khalilzadeh M; Takzaree N; Dehpour AR
Daru; 2022 Dec; 30(2):303-310. PubMed ID: 36104653
[TBL] [Abstract][Full Text] [Related]
6. Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients: A Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis.
Centanni M; van de Velde ME; Uittenboogaard A; Kaspers GJL; Karlsson MO; Friberg LE
Clin Pharmacokinet; 2024 Feb; 63(2):197-209. PubMed ID: 38141094
[TBL] [Abstract][Full Text] [Related]
7. Characterising vincristine-induced peripheral neuropathy in adults: symptom development and long-term persistent outcomes.
Li T; Trinh T; Bosco A; Kiernan MC; Goldstein D; Park SB
Support Care Cancer; 2024 Apr; 32(5):278. PubMed ID: 38592525
[TBL] [Abstract][Full Text] [Related]
8. Prevention of vincristine-induced peripheral neuropathy by protecting the endothelial glycocalyx shedding.
Ohmura K; Kinoshita T; Tomita H; Okada H; Shimizu M; Mori K; Taniguchi T; Suzuki A; Iwama T; Hara A
Biochem Biophys Res Commun; 2024 Jan; 691():149286. PubMed ID: 38016339
[TBL] [Abstract][Full Text] [Related]
9. Acute, long-term or non-vincristine-induced peripheral neuropathy among non-Hodgkin lymphoma survivors: Symptoms, daily activities, functional status, and quality of life.
Su YC; Lai YH; Hsieh ST; Teng CJ; Lee YH
Eur J Oncol Nurs; 2024 Apr; 69():102540. PubMed ID: 38461728
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous quantification and pharmacokinetics of vincristine and its major metabolite M1 in Chinese pediatric ALL patients by LC-MS/MS.
Yuan Y; Chen C; You G; Yao R; Zhu X; Wu X; Wu J; Zhao W; Li Z; Zhang S
J Pharm Biomed Anal; 2023 Sep; 234():115578. PubMed ID: 37459833
[TBL] [Abstract][Full Text] [Related]
11. Targeting a xenobiotic transporter to ameliorate vincristine-induced sensory neuropathy.
Li Y; Drabison T; Nepal M; Ho RH; Leblanc AF; Gibson AA; Jin Y; Yang W; Huang KM; Uddin ME; Chen M; DiGiacomo DF; Chen X; Razzaq S; Tonniges JR; McTigue DM; Mims AS; Lustberg MB; Wang Y; Hummon AB; Evans WE; Baker SD; Cavaletti G; Sparreboom A; Hu S
JCI Insight; 2023 Jul; 8(14):. PubMed ID: 37347545
[TBL] [Abstract][Full Text] [Related]
12. Immune-mediated vincristine-induced neuropathy: Unlocking therapies.
Savelieff MG; Feldman EL
J Exp Med; 2021 May; 218(5):. PubMed ID: 33751022
[TBL] [Abstract][Full Text] [Related]
13. A Metabolomics Approach for Early Prediction of Vincristine-Induced Peripheral Neuropathy.
Verma P; Devaraj J; Skiles JL; Sajdyk T; Ho RH; Hutchinson R; Wells E; Li L; Renbarger J; Cooper B; Ramkrishna D
Sci Rep; 2020 Jun; 10(1):9659. PubMed ID: 32541868
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of vincristine-induced peripheral neuropathy in children with cancer: Turkish validity and reliability study.
Özdemir B; Gerçeker GÖ; Özdemir EZ; Yildirim BG; Ören H; Yiş U; Günay Ç; Thomas GÖ
J Pediatr Nurs; 2023; 72():185-190. PubMed ID: 37076371
[TBL] [Abstract][Full Text] [Related]
15. Severe Vincristine-Induced Peripheral Neuropathic Weakness in Both Lower Limbs in an Asian Adolescent with
Zhang D; Bai J
Pharmgenomics Pers Med; 2024; 17():125-131. PubMed ID: 38645702
[TBL] [Abstract][Full Text] [Related]
16. Vincristine-Induced Peripheral Neuropathy in Children With Malignancy and the Effect of Missed Doses on Treatment Success.
Eker N; Ozturk G
Cureus; 2023 Sep; 15(9):e46063. PubMed ID: 37771936
[TBL] [Abstract][Full Text] [Related]
17. Without ENMG, detecting pediatric vincristine neuropathy is a challenge.
Viinikainen K; Isohanni P; Kanerva J; Lönnqvist T; Lauronen L
Clin Neurophysiol Pract; 2024; 9():94-101. PubMed ID: 38440119
[TBL] [Abstract][Full Text] [Related]
18. Protective effect of selenium on vincristine-induced peripheral neuropathy in PC12 cell line.
Jafari D; Eslami SS; Malih S; Tarighi P
Cytotechnology; 2022 Oct; 74(5):539-547. PubMed ID: 36238267
[TBL] [Abstract][Full Text] [Related]
19. Vincristine-based nanoformulations: a preclinical and clinical studies overview.
Shukla R; Singh A; Singh KK
Drug Deliv Transl Res; 2024 Jan; 14(1):1-16. PubMed ID: 37552393
[TBL] [Abstract][Full Text] [Related]
20. Netazepide, an Antagonist of Cholecystokinin Type 2 Receptor, Prevents Vincristine-Induced Sensory Neuropathy in Mice.
Bernard A; Mroué M; Bourthoumieu S; Boyce M; Richard L; Sturtz F; Demiot C; Danigo A
Pharmaceuticals (Basel); 2024 Jan; 17(2):. PubMed ID: 38399359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
